Analysts Set Expectations for CRSP FY2029 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Brookline Capital Management issued their FY2029 earnings estimates for shares of CRISPR Therapeutics in a report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings of $63.56 per share for the year. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.13) per share.

A number of other equities research analysts have also recently issued reports on the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. JMP Securities restated a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Barclays cut their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $78.38.

CRISPR Therapeutics Trading Down 1.5 %

Shares of NASDAQ CRSP opened at $41.29 on Wednesday. The company has a market cap of $3.52 billion, a price-to-earnings ratio of -14.59 and a beta of 1.68. The stock’s 50 day simple moving average is $46.50 and its 200 day simple moving average is $48.88. CRISPR Therapeutics has a 12-month low of $38.20 and a 12-month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter last year, the company posted ($1.41) earnings per share.

Insider Transactions at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. The trade was a 1.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,382 shares of company stock valued at $2,744,179 in the last quarter. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Larson Financial Group LLC boosted its stake in CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after purchasing an additional 276 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in shares of CRISPR Therapeutics in the second quarter worth $35,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics in the third quarter worth $40,000. Darwin Wealth Management LLC purchased a new position in shares of CRISPR Therapeutics during the third quarter valued at $43,000. Finally, National Bank of Canada FI lifted its stake in CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after acquiring an additional 220 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.